Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

95.61USD
23 Feb 2018
Change (% chg)

$1.83 (+1.95%)
Prev Close
$93.78
Open
$94.10
Day's High
$95.66
Day's Low
$93.96
Volume
1,654,469
Avg. Vol
2,738,386
52-wk High
$147.13
52-wk Low
$88.34

Select another date:

Wed, Feb 21 2018

BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition

* CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​ Source text for Eikon: Further company coverage:

BRIEF-Amunix Operating Says Has Entered Into A Licensing Agreement With Celgene

* AMUNIX OPERATING SAYS HAS ENTERED INTO A LICENSING AGREEMENT WITH CELGENE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Celularity Announces Formation Of Co With $250 Mln In Funding From Celgene, United Therapeutics, Others

* ‍CELULARITY ANNOUNCES $250 MILLION IN FUNDING TO DELIVER TREATMENTS FOR CANCER, INFLAMMATORY AND DEGENERATIVE DISEASES, AND FUNCTIONAL REGENERATION​

BRIEF-Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients

* OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS

BRIEF-Celgene Corp Elects John Weiland To Its Board

* CELGENE CORPORATION ELECTS JOHN WEILAND TO ITS BOARD OF DIRECTORS

BRIEF-Celgene Announces Additional $5 Billion Share Repurchase Authorization

* CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION

BRIEF-Celgene Prices $4.5 Billion Of Senior Unsecured Notes

* CELGENE CORP - ANNOUNCED PRICING OF FOUR SERIES OF SENIOR UNSECURED NOTES

BRIEF-Celgene Corp Announces Positive Results From The Pivotal Phase III ‘Optimismm’ Study Of Pomalyst/Imnovid

* CELGENE CORPORATION ANNOUNCES POSITIVE RESULTS FROM THE PIVOTAL PHASE III ‘OPTIMISMM’ STUDY OF POMALYST/IMNOVID® FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA

BRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics

* CELGENE CORPORATION COMMENCES TENDER OFFER FOR JUNO THERAPEUTICS, INC.

BRIEF-Celgene Says Entered Into Settlement With Actavis​

* CELGENE - ENTERED INTO SETTLEMENT WITH ACTAVIS LLC TO TERMINATE PENDING PATENT LITIGATION, IPR CHALLENGES RELATING TO CERTAIN PATENTS FOR ABRAXANE​

Select another date: